These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3982211)

  • 21. Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.
    Marshall E; Woolford LB; Lord BI
    Br J Cancer; 1997; 75(12):1715-20. PubMed ID: 9192972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R; Bony V; Lopez M
    Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
    [No Abstract]   [Full Text] [Related]  

  • 23. The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of cyclophosphamide.
    Eliason JF; Inoue T; Kubota A; Teelmann K; Horii I; Hartmann D
    Int J Cancer; 1993 Sep; 55(3):492-7. PubMed ID: 8375933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide-induced alterations of bone marrow endothelium: implications in homing of marrow cells after transplantation.
    Shirota T; Tavassoli M
    Exp Hematol; 1991 Jun; 19(5):369-73. PubMed ID: 2026187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematoprotective effect of boron on cyclophosphamide toxicity in rats.
    Cengiz M
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):62-65. PubMed ID: 29729695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin 1 alpha (IL-1) and macrophage colony-stimulating factor (M-CSF) accelerate recovery from multiple drug-induced myelosuppression.
    Kovacs CJ; Kerr JA; Daly BM; Evans MJ; Johnke RM
    Anticancer Res; 1998; 18(3A):1805-12. PubMed ID: 9673408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice.
    Matsunaga T; Sakamaki S; Kuga T; Kuroda H; Kusakabe T; Akiyama T; Konuma Y; Hirayama Y; Kobune M; Kato J; Sasaki K; Kogawa K; Koyama R; Niitsu Y
    Hum Gene Ther; 2000 Aug; 11(12):1671-81. PubMed ID: 10954901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM).
    Pessina A; Piccirillo M; Mineo E; Catalani P; Gribaldo L; Marafante E; Neri MG; Raimondi A
    Life Sci; 1999; 65(5):513-23. PubMed ID: 10462078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effects of swainsonine on murine survival and bone marrow proliferation during cytotoxic chemotherapy.
    Oredipe OA; White SL; Grzegorzewski K; Gause BL; Cha JK; Miles VA; Olden K
    J Natl Cancer Inst; 1991 Aug; 83(16):1149-56. PubMed ID: 1909378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model.
    Fan C; Georgiou KR; Morris HA; McKinnon RA; Keefe DMK; Howe PR; Xian CJ
    Breast Cancer Res Treat; 2017 Aug; 165(1):41-51. PubMed ID: 28550626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dideoxycytidine toxicity on mouse hemopoietic progenitors.
    Mencoboni M; Lerza R; Bogliolo G; Flego G; Gasparini L; Pannacciulli I
    In Vivo; 1990; 4(3):171-3. PubMed ID: 1966801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
    Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
    Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hemoprotection with dicarbamine: shielding of bone marrow hemopoietic cells from apoptosis and induction of cell differentiation in myelosuppressive effect of cyclophosphamide].
    Raĭkhlin NT; Bukaeva IA; Sitdikova SM; Nebol'sin VE
    Vopr Onkol; 2011; 57(4):497-500. PubMed ID: 22191241
    [No Abstract]   [Full Text] [Related]  

  • 34. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of disulfiram on cyclophosphamide-mediated myeloid toxicity.
    Gamelli RL; Ershler WB; Hacker MP; Foster RS
    Cancer Chemother Pharmacol; 1986; 16(2):153-5. PubMed ID: 3948301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of erythropoietic activation on the hemotoxicity of cyclophosphamide].
    Bogliolo G; Ronco D; Massa G; Dolcino G; Mansi C; Pannacciulli I
    Arch Maragliano Patol Clin; 1973; 29(2):153-7. PubMed ID: 4808341
    [No Abstract]   [Full Text] [Related]  

  • 37. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice.
    Ellefson DD; diZerega GS; Espinoza T; Roda N; Maldonado S; Rodgers KE
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):15-24. PubMed ID: 14569417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Early and late effects of the cytogenetic action of doxorubicin].
    Klimova MIu; Novitskiĭ VV; Gol'dberg ED
    Antibiot Khimioter; 1990 Jan; 35(1):30-2. PubMed ID: 2334242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic precursor cells in mice treated with 4-demethoxydaunorubicin and doxorubicin.
    Massa G; Bogliolo G; D'Amore F; Muzzulini C; Ghio R; Pannacciulli I
    J Natl Cancer Inst; 1982 Jun; 68(6):971-6. PubMed ID: 6953276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failure of N-acetylcysteine to protect against cis-dichlorodiammineplatinum(II)-induced hematopoietic toxicity in mice.
    Lerza R; Bogliolo G; Muzzulini C; Pannacciulli I
    Life Sci; 1986 May; 38(19):1795-800. PubMed ID: 3702608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.